Search

Displaying results 2181 - 2190 of 10000 in total
  1. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma. … [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging

  2. Drug

    Barnidipine

    go.drugbank.com/drugs/DB09227
    Investigational

    Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall [L1131] and selectivity against cardiovascular L-type … It is available in modified-release oral tablets under the brand name Vasexten to be taken once daily in the morning.

  3. Drug

    Bardoxolone

    go.drugbank.com/drugs/DB12651
    Investigational

    In contrast, Bardoxolone in normal cells induces protective antioxidant/anti-inflammatory responses. … Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors.

  4. Drug

    Trolamine salicylate

    go.drugbank.com/drugs/DB11079
    Approved

    Trolamine salicylate serves as an active ingredient in topical over-the-counter products for temporary management of mild to moderate muscular and joint pains. … It is a topical analgesic used for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises.

    Mixtures: Arthritis Extra Strength Roll-ON LotionProducts: Teds Topical Pain Gel Roll On, Uncle Buds Roll-On Pain Relief
  5. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. … [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

  6. Drug

    Capsicum oleoresin

    go.drugbank.com/drugs/DB11131
    Approved

    Capsicum oleoresin is contained in pepper sprays when suspended in water, and acts an active lachrymatory agent that induces irritation, lacrimation, pain, and temporary blindness when in contact with … Capsicum oleoresin is an oily organic resin derived from the fruit of plants in the Capsicum genus, such as chilli peppers.

    Mixtures: DermacinRx Lexitral PharmaPak II
  7. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Vanzacaftor was first approved by the US FDA in December 2024 in combination with another CFTR corrector - [tezacaftor], which binds to a different site than vanzacaftor - and [deutivacaftor

  8. Drug

    Dosulepin

    go.drugbank.com/drugs/DB09167
    ApprovedInvestigational

    It is not FDA-approved due to low therpeutic index and significant toxicity in overdose. … Its hydrochloride form is a common active ingredient in different drug formulations.

    Synonyms: (3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
  9. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.

  10. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    [L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous